MedTrace Logo

Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)

NCT01875770 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 47

Last updated 2021-10-12

No results posted yet for this study

Summary

This research is being done to assess the long term prognosis of patients treated with ranibizumab for edema due to retinal vein occlusion.

Conditions

  • Retinal Vein Occlusion

Sponsors & Collaborators

Principal Investigators

  • Peter Campochiaro, MD · Johns Hopkins University

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2018-10-11
Completion
2021-03-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01875770 on ClinicalTrials.gov